Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels. HealthDay News — Drugmaker Eli Lilly plans to buy Verve ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Eli Lilly (NYSE: LLY), a prominent player in the pharmaceuticals industry with a market capitalization of $710 billion, has reached an agreement to acquire Verve Therapeutics (NASDAQ: VERV), marking ...

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade) Stephen Ayers Tue, Jun. 17. Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) ...

Eli Lilly to acquire Verve Therapeutics for up to $1.3B SA News Tue, Jun. 17. Verve Therapeutics, Inc. SEC Filing - Quarterly Report (10-Q) May 14, 2025 SEC Filings Wed, May 14.

A common blood test can flag early Alzheimer's disease patients who are four times more likely to experience rapid brain ...

People who have frequent nightmares appear to have a tripled risk of premature death, according to a new study.